Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilaprazole + levosulpiride
- Development stage
- Unknown
- Lead developer
- Ritz Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ilariz-LSR is an oral fixed-dose combination capsule developed and marketed by Ritz Pharma. It contains **ilaprazole**, a proton pump inhibitor (PPI), and **levosulpiride**, a prokinetic agent, in a sustained-release formulation. The product is indicated for the management of acid-related disorders such as peptic ulcers and gastroesophageal reflux disease (GERD), as well as gastroparesis. Ilaprazole acts by covalently binding to the H+/K+-ATPase enzyme (the gastric proton pump) in parietal cells, effectively blocking the final step of acid production. Levosulpiride acts as a selective antagonist at dopamine D2 receptors in the gastrointestinal tract, which promotes gastric emptying and improves motility, thereby addressing symptoms of dyspepsia and delayed gastric transit.
- Brand names
- Ilariz-LSR
- Other names
- Ilaprazole and Levosulpiride SR capsules
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)HTR4 (5-Hydroxytryptamine receptor 4)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)PBK (TOPK)
Beyond the preview
Go deeper on ilaprazole + levosulpiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilaprazole + levosulpiride.